<DOC>
	<DOCNO>NCT00225615</DOCNO>
	<brief_summary>The primary objective trial evaluate safety tolerability long-term Phenoptin treatment subject PKU .</brief_summary>
	<brief_title>A Phase 3 , Multicenter , Open-Label Extension Study Phenoptin Subjects With PKU Who Have Elevated Phenylalanine Levels</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>8 year age old Prior successful participation Study PKU003 Willing able provide write informed consent assent write informed consent ( require ) parent legal guardian For female childbearing potential : Negative urine pregnancy test within 24 hour prior enrollment . Women use acceptable birth control measure must agree continue use measure participate study Willing able comply study procedure Willing continue current diet unchanged participate study Perceived unreliable unavailable study participation , age 18 , parent legal guardian perceive unreliable unavailable Withdrew , otherwise successfully complete , study PKU003 , except subject remove study blood Phe exceed alert level Expected require investigational agent vaccine prior completion schedule study assessment Pregnant breastfeeding , plan pregnancy Concurrent disease condition would interfere study participation safety ( e.g. , seizure disorder , oral steroiddependent asthma condition require oral parenteral corticosteroid administration , insulindependent diabetes ) Requirement concomitant treatment drug know inhibit folate synthesis ( e.g. , methotrexate ) Concurrent use levodopa</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Phenylalanine Hydroxylase</keyword>
</DOC>